Nektar Therapeutics Azioni (NASDAQ: NKTR)

Ultime notizie per Nektar Therapeutics (NASDAQ:NKTR) Azioni

NEKTAR THERAPEUTICS

Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

News

Offerings

NKTR

Nektar Therapeutics: Files For Mixed Shelf Offering Of Up To $300M

WIIM

Nekar Therapeutics shares are trading higher after Oppenheimer upgraded the stock from Perform to Outperform and announced a price target of $6.

Oppenheimer analyst Jay Olson upgrades Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) from Perform to Outperform and announces $6 price target.

Upgrades

Price Target

Analyst Ratings

Oppenheimer Upgrades Nektar Therapeutics to Outperform, Announces $6 Price Target

<h3>Gainers</h3>
<ul>
<li>Cellectis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLLS#NASDAQ">CLLS</a>) shares moved upwards by 17.1% to $1.51 during Friday's pre-market session. The company's market cap stands at $151.1 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) stock rose 15.46% to $1.12. The company's market cap stands at $18.6 million. </li>
<li>Eton Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) stock increased by 14.72% to $16.75. The company's market cap stands at $436.3 million. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) stock rose 11.64% to $0.91. The company's market cap stands at $167.9 million. The company's, Q4 earnings came out 2 days ago. </li>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) stock rose 10.67% to $1.14. The market value of their outstanding shares is at $17.5 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) stock rose 10.09% to $3.6. The company's market cap stands at $3.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock declined by 25.6% to $0.32 during Friday's pre-market session. The company's market cap stands at $1.5 million. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) shares decreased by 16.33% to $2.46. The company's market cap stands at $142.3 million. The company's, Q4 earnings came out today. </li>
<li>Sutro Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) stock fell 16.0% to $1.05. The company's market cap stands at $86.5 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) stock decreased by 15.49% to $3.41. The market value of their outstanding shares is at $119.4 million. </li>
<li>Olema Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLMA#NASDAQ">OLMA</a>) shares decreased by 15.34% to $3.7. The company's market cap stands at $274.7 million. </li>
<li>Marker Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>) stock decreased by 15.26% to $1.0. The market value of their outstanding shares is at $10.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADGM

AIRS

CLLS

ETON

IRIX

MRKR

OLMA

REVB

SERA

SHPH

STRO

12 Health Care Stocks Moving In Friday's Pre-Market Session

4 analysts have expressed a variety of opinions on Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $5.88, a high estimate of $6.50, and a low estimate of $4.00. This current average has decreased by 9.54% from the previous average price target of $6.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1741870850_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Nektar Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.50</td>
<td>$6.50</td>
</tr>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.50</td>
<td>$6.50</td>
</tr>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.50</td>
<td>$6.50</td>
</tr>
<tr>
<td>Mayank Mamtani</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$4.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Nektar Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Nektar Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Nektar Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Nektar Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NKTR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Nektar Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Nektar Therapeutics's Background</h2>
Nektar Therapeutics is a pharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is focused on discovering and developing medicines in the field of immunotherapy. Its clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255).
<h3>Nektar Therapeutics: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Negative Revenue Trend: Examining Nektar Therapeutics's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -0.08% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Nektar Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -153.61%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -57.64%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Nektar Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -11.38%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Nektar Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 2.21. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Nektar Therapeutics: Insights From 4 Financial Analysts

HC Wainwright &amp; Co. analyst Arthur He reiterates Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) with a Buy and maintains $6.5 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $6.5 Price Target

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.17) by 11.76 percent. The company reported quarterly sales of $29.200 million which missed the analyst consensus estimate of $29.860 million by 2.21 percent. This is a 22.25 percent increase over sales of $23.885 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Nektar Therapeutics Q4 2024 Adj. EPS $(0.15) Beats $(0.17) Estimate, Sales $29.200M Miss $29.860M Estimate

<h3>Companies Reporting Before The Bell</h3>
• EHang Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) is projected to report quarterly loss at $0.07 per share on revenue of $23.36 million. 
• Hello Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>) is projected to report quarterly earnings at $0.21 per share on revenue of $365.05 million. 
• Chicago Atlantic Real (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) is estimated to report quarterly earnings at $0.56 per share on revenue of $14.19 million. 
• Waterdrop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) is expected to report earnings for its fourth quarter. 
• Upland Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPLD#NASDAQ">UPLD</a>) is projected to report quarterly earnings at $0.20 per share on revenue of $67.84 million. 
• VNET Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $284.88 million. 
• Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) is likely to report quarterly earnings at $0.06 per share on revenue of $107.94 million. 
• Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $200.59 million. 
• Arcos Dorados Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCO#NYSE">ARCO</a>) is likely to report quarterly earnings at $0.21 per share on revenue of $1.15 billion. 
• Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $194.15 million. 
• OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $30.36 million. 
• Navigator Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVGS#NYSE">NVGS</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $120.87 million. 
• ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) is projected to report quarterly earnings at $0.78 per share on revenue of $2.09 billion. 
• Smith Douglas Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDHC#NYSE">SDHC</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $265.85 million. 
• Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) is expected to report quarterly loss at $0.03 per share on revenue of $32.37 million. 
• ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) is expected to report quarterly earnings at $3.49 per share on revenue of $2.02 billion. 
• Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) is projected to report quarterly earnings at $0.13 per share on revenue of $161.60 million. 
• National Energy Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NESR#NASDAQ">NESR</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $339.84 million. 
• iRobot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) is expected to report quarterly loss at $1.73 per share on revenue of $171.00 million. 
• Ondas Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONDS#NASDAQ">ONDS</a>) is expected to report quarterly loss at $0.09 per share on revenue of $5.75 million. 
• BingEx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLX#NASDAQ">FLX</a>) is expected to report earnings for its fourth quarter. 
• InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) is likely to report quarterly loss at $0.19 per share on revenue of $1.82 million. 
• United Homes Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>) is estimated to report earnings for its fourth quarter. 
• Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $24.15 million. 
• MagnaChip Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MX#NYSE">MX</a>) is expected to report quarterly loss at $0.19 per share on revenue of $61.57 million. 
<h3>Companies Reporting After The Bell</h3>
• Vasta Platform (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTA#NASDAQ">VSTA</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $110.28 million. 
• KLX Energy Services Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLXE#NASDAQ">KLXE</a>) is expected to report quarterly loss at $0.80 per share on revenue of $168.90 million. 
• Algoma Steel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTL#NASDAQ">ASTL</a>) is expected to report earnings for its third quarter. 
• Comtech Telecom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) is projected to report quarterly loss at $0.25 per share on revenue of $129.53 million. 
• Aris Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARIS#NYSE">ARIS</a>) is estimated to report earnings for its fourth quarter. 
• Legacy Housing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGH#NASDAQ">LEGH</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $44.59 million. 
• Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) is expected to report quarterly loss at $0.19 per share on revenue of $36.66 million. 
• Montauk Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTK#NASDAQ">MNTK</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $56.32 million. 
• Ellington Credit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EARN#NYSE">EARN</a>) is expected to report quarterly earnings at $0.30 per share on revenue of $9.65 million. 
• FreightCar America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIL#NASDAQ">RAIL</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $152.02 million. 
• PHX Minerals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHX#NYSE">PHX</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $8.93 million. 
• Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) is expected to report quarterly earnings at $1.82 per share on revenue of $1.64 billion. 
• SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) is estimated to report quarterly loss at $0.21 per share on revenue of $222.33 million. 
• ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) is likely to report earnings for its fourth quarter. 
• UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $425.34 million. 
• SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) is estimated to report quarterly loss at $1.50 per share on revenue of $710 thousand. 
• RCM Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCMT#NASDAQ">RCMT</a>) is expected to report quarterly earnings at $0.83 per share on revenue of $79.00 million. 
• Beauty Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKIN#NASDAQ">SKIN</a>) is projected to report quarterly loss at $0.09 per share on revenue of $77.45 million. 
• Fathom Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTHM#NASDAQ">FTHM</a>) is projected to report quarterly loss at $0.17 per share on revenue of $84.70 million. 
• Cardlytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDLX#NASDAQ">CDLX</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $63.63 million. 
• Biote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTMD#NASDAQ">BTMD</a>) is likely to report quarterly earnings at $0.17 per share on revenue of $51.20 million. 
• Limoneira (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>) is projected to report quarterly loss at $0.17 per share on revenue of $40.70 million. 
• Calavo Growers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGW#NASDAQ">CVGW</a>) is expected to report quarterly earnings at $0.29 per share on revenue of $161.55 million. 
• KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) is likely to report quarterly loss at $0.02 per share on revenue of $8.89 million. 
• American Eagle Outfitters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) is likely to report quarterly earnings at $0.51 per share on revenue of $1.60 billion. 
• Berry Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRY#NASDAQ">BRY</a>) is expected to report quarterly earnings at $0.15 per share on revenue of $173.00 million. 
• Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) is projected to report quarterly loss at $0.19 per share on revenue of $108.91 million. 
• Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) is projected to report quarterly earnings at $4.97 per share on revenue of $5.66 billion. 
• electroCore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECOR#NASDAQ">ECOR</a>) is expected to report quarterly loss at $0.34 per share on revenue of $7.29 million. 
• AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $9.73 million. 
• BGSF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGSF#NYSE">BGSF</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $67.65 million. 
• CI&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CINT#NYSE">CINT</a>) is projected to report earnings for its fourth quarter. 
• Companhia Siderurgica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SID#NYSE">SID</a>) is projected to report quarterly loss at $0.09 per share on revenue of $1.94 billion. 
• Performant Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHLT#NASDAQ">PHLT</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $34.15 million. 
• Urgently (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULY#NASDAQ">ULY</a>) is expected to report earnings for its fourth quarter. 
• Assertio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASRT#NASDAQ">ASRT</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $28.67 million. 
• Quest Resource Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRHC#NASDAQ">QRHC</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $73.63 million. 
• CPS Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPSH#NASDAQ">CPSH</a>) is estimated to report earnings for its fourth quarter. 
• Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>) is expected to report earnings for its third quarter. 
• Zedge (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZDGE#AMEX">ZDGE</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $7.71 million. 
• NextNav (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NN#NASDAQ">NN</a>) is expected to report quarterly loss at $0.14 per share on revenue of $1.73 million. 
• Monogram Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRM#NASDAQ">MGRM</a>) is estimated to report earnings for its fourth quarter. 
• Fossil Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOSL#NASDAQ">FOSL</a>) is likely to report earnings for its fourth quarter. 
• Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $29.00 million. 
• Aris Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMN#AMEX">ARMN</a>) is likely to report earnings for its fourth quarter. 
• Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $116.82 million. 
• Tilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLYS#NYSE">TLYS</a>) is expected to report quarterly loss at $0.29 per share on revenue of $159.90 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADBE

AEYE

AMRN

ANIK

ARCO

ARIS

ARMN

ASRT

ASTL

BGSF

BRLT

BTMD

CDLX

CINT

CMTL

CPSH

CVGW

EARN

ECOR

FOSL

FTHM

HBIO

IRBT

KEQU

KLXE

KRMD

LEGH

LMNR

LOGC

MGRM

MNTK

MOMO

NESR

NSPR

NVGS

ONDS

OPRX

PATH

PHLT

QRHC

RAIL

RCMT

REFI

SDHC

SEAT

SKIN

SNES

TLYS

UPLD

VNET

VSTA

ZDGE

Earnings Scheduled For March 12, 2025

Nektar Therapeutics Announces Completion Of Target Enrollment In REZOLVE-AA Phase 2b Clinical Trial Of Rezpegaldesleukin In Patients With Severe-to-Very Severe Alopecia Areata

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) and TrialNet, an international clinical trial network at the forefront of diabetes research, today announced a new collaboration agreement to evaluate Nektar's rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus (T1D).
&nbsp;
Rezpegaldesleukin is a novel agonistic T regulatory (Treg) cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immune balance by directly expanding functional Treg cells and engaging multiple immunoregulatory pathways. Tregs are known to play a key role in the pathogenesis of T1D.1
Under the agreement, TrialNet will conduct the Phase 2 randomized, double-blind, placebo-controlled, clinical trial to investigate the safety and potential efficacy of rezpegaldesleukin in approximately 70 adults and children with new onset stage 3 T1D. Nektar will supply rezpegaldesleukin for the trial and will provide support for the study, including pharmacokinetic and other analyses. Nektar will retain all rights to the rezpegaldesleukin program under the collaboration.

Nektar Therapeutics and TrialNet Partner to Study Rezpegaldesleukin for Type 1 Diabetes

Nektar Therapeutics shares are trading higher after the company received Fast Track designation for Rezpegaldesleukin for the treatment of moderate-to-severe atopic dermatitis.

Biotech

Health Care

General

The FDA Has Granted Fast Track Designation To Nektar Therapeutics' Rezpegaldesleukin For Adult And Pediatric Patients 12 Years Of Age And Older With Moderate-to-severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled With Topical Prescription Therapies Or When Those Therapies Are Not Advisable

<h3>Gainers</h3>
<ul>
<li>PureTech Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>) stock rose 30.9% to $25.0 during Monday's pre-market session. The market value of their outstanding shares is at $598.5 million. </li>
<li>Telix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLX#NASDAQ">TLX</a>) shares increased by 21.88% to $22.0. The market value of their outstanding shares is at $7.3 billion. </li>
<li>Microbot Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBOT#NASDAQ">MBOT</a>) shares rose 18.43% to $3.02. The market value of their outstanding shares is at $84.6 million. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) shares rose 16.84% to $0.79. The market value of their outstanding shares is at $145.7 million. </li>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) shares rose 12.74% to $0.49. The company's market cap stands at $9.9 million. </li>
<li>Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) stock increased by 12.5% to $3.24. The company's market cap stands at $129.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) shares declined by 57.6% to $3.3 during Monday's pre-market session. The company's market cap stands at $200.8 million. </li>
<li>Precipio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPO#NASDAQ">PRPO</a>) stock declined by 24.87% to $5.0. The market value of their outstanding shares is at $7.4 million. </li>
<li>Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) stock fell 19.59% to $11.21. The company's market cap stands at $862.6 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares decreased by 17.55% to $2.35. The company's market cap stands at $3.6 million. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) shares fell 15.13% to $1.01. The market value of their outstanding shares is at $33.0 million. </li>
<li>OptiNose (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) stock declined by 12.05% to $5.11. The market value of their outstanding shares is at $51.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CUTR

CYTH

MBOT

OPTN

PLRX

PRPO

PRTC

REPL

SLDB

12 Health Care Stocks Moving In Monday's Pre-Market Session

"We are pleased to announce that we reached our target enrollment for our 396-patient Phase 2b trial of rezpegaldesleukin," said Howard W. Robin, President and CEO of Nektar Therapeutics.&nbsp;
"We look forward to announcing the topline data from the 16-week induction treatment period in this study in the second quarter of 2025."
&nbsp;

Nektar Therapeutics Completes Target Enrollment In REZOLVE-AD Phase 2B Study Of Rezpegaldesleukin In Patients With Atopic Dermatitis

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays analyst Paul Kearney initiated coverage on Levi Strauss &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) with an Overweight rating and announced a price target of $24. Levi Strauss shares closed at $17.67 on Tuesday. <a href="https://www.benzinga.com/quote/levi/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities analyst Asthika Goonewardene initiated coverage on Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) with a Buy rating and announced a price target of $35. Summit Therapeutics shares closed at $18.16 on Tuesday. <a href="https://www.benzinga.com/quote/SMMT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel analyst Annabel Samimy initiated coverage on Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) with a Buy rating and announced a price target of $18. Altimmune shares closed at $7.31 on Tuesday. <a href="https://www.benzinga.com/quote/alt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B. Riley Securities analyst Mayank Mamtani initiated coverage on Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) with a Buy rating and announced a price target of $4. Nektar Therapeutics shares closed at $1.19 on Tuesday. <a href="https://www.benzinga.com/quote/nkKR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Silvan Tuerkcan initiated coverage on Context Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) with a Market Outperform rating and announced a price target of $4. Context Therapeutics shares closed at $1.09 on Tuesday. <a href="https://www.benzinga.com/quote/cntx/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying LEVI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08073956/image-46-1024x587.png" alt="" class="wp-image-723832" style="width:553px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08073956/image-46-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08073956/image-46-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08073956/image-46-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08073956/image-46.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42846607/bank-of-new-york-mellon-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Bank of New York Mellon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Initiation

Pre-Market Outlook

Trading Ideas

CNTX

LEVI

SMMT

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

B. Riley Securities analyst Mayank Mamtani initiates coverage on Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) with a Buy rating and announces Price Target of $4.

B. Riley Securities Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target of $4

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) today announced results of its Phase 2 proof-of-concept study evaluating NKTR-255 as an adjuvant treatment to enhance complete response rate (CRR) and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory (R/R) Large B-cell Lymphoma (LBCL) at the 66th ASH Annual Meeting and Exposition in San Diego, California.
73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months
NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area under the curve (AUC) 0-15 days post-administration being 5.8-fold greater than placebo-controls
&nbsp;

Nektar Therapeutics Announced NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma At ASH Meeting; 73% Of NKTR-255 Treatment Group Vs 50% Of Placebo Group Achieved Complete Response At 6 Months

- NKTR-422 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions -
SAN FRANCISCO, Nov. 18, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) today announced its oral presentation highlighting preclinical data on NKTR-422 at the 2024 American College of Rheumatology (ACR)&nbsp;conference, being held in Washington, D.C. from November 14-19, 2024.
NKTR-422 is a novel modified&nbsp;hematopoietic colony stimulating factor (CSF) protein engineered to selectively modulate resolution processes of inflammation by targeting the expansion, reprograming and activation of anti-inflammatory tissue resident macrophages.
Currently approved inflammatory disease therapies are not designed to achieve inflammation resolution or tissue repair, which are both required for remission.1 Nektar has identified a CSF-1R agonist with a differentiated pharmacokinetic (PK)/pharmacodynamic (PD) profile compared to the native CSF-1 cytokine. Reduced clearance enables sustained PD activity from a single dose, unlike historical multiple dose per day necessary regimens of recombinant human CSF-1 administration. This CSF-1R agonist, NKTR-422, demonstrated inflammation resolution and tissue repair markers induction in tissue resident macrophages without induction of monocytosis and enhanced the efficacy of inflammatory cytokine blockade in rodent models.

Nektar Therapeutics Presents First Preclinical Data From Novel CSF-1 Program, NKTR-422, At 2024 American College Of Rheumatology  Convergence; NKTR-422 Demonstrated Inflammation Resolution And Tissue Repair In Multiple Preclinical Models Of Chronic Inflammatory Conditions

Press Releases

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

Contracts

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Comments

Nektar Therapeutics

Notizie

Ultime notizie per Nektar Therapeutics (NASDAQ:NKTR) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO